Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Valuation differences halt EQT’s Oxford Biomedica takeover push
Valuation differences halt EQT’s Oxford Biomedica takeover push EQT has opted not to proceed with a takeover offer for Oxford Biomedica after the British cell and gene therapy manufacturer rejected four separate proposals, Reuters reported. Oxford Biomedica confirmed...
Novacap closes $3.8bn Tech Fund VII, surpassing target by over $1bn
Novacap closes $3.8bn Tech Fund VII, surpassing target by over $1bn Novacap has closed its Technologies Fund VII at nearly $3.8bn, exceeding its $2.75bn target by more than $1bn in under a year, the firm announced. The vehicle marks Novacap’s largest fund to date and...
L Catterton partner Todd Bartee takes helm at Tonal as private equity reshapes connected fitness
L Catterton partner Todd Bartee takes helm at Tonal as private equity reshapes connected fitness L Catterton has strengthened its operational oversight at portfolio company Tonal by appointing Operating Partner Todd Bartee as Chief Executive Officer. Bartee succeeds...